MedBridgeNZFacing recurrent Glioblastoma (GBM)? In 2026, new multi-target CAR-T clinical trials are offering alternative evaluation pathways. As a professional medical concierge provider, MedBridgeNZ helps patients safely navigate Medical Tourism China.
Read our guide: https://zurl.co/NoHms
#Glioblastoma #CARTtherapy #NeuroOncology #ClinicalTrials #MedicalConcierge #MedBridgeNZ #MedicalTourismChina #ChinaMedicalTourism
Accessing CAR-T Therapy for Glioblastoma in China (2026)
Key Takeaways • Between 2022 and 2025, over 66 CAR-T clinical trials targeting glioblastoma were launched across top medical institutions in China. • Chinese clinical trials utilize multi-antigen targeting (dual or tri-specific CAR-T cells) to address tumor antigen escape. • Advanced manufacturing platforms, such as FasTCAR, have compressed cell production times from several weeks to 24-36 hours. • The estimated cost for experimental CAR-T therapy in Chinese investigator-initiated trials (IITs)